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Abstract
Viruses have evolved various strategies to escape the antiviral activity of type I interferons (IFN-α/β). For measles virus, this function is
carried by the polycistronic gene P that encodes, by an unusual editing strategy, for the phosphoprotein P and the virulence factor V (MV-V).
MV-V prevents STAT1 nuclear translocation by either sequestration or phosphorylation inhibition, thereby blocking IFN-α/β pathway. We
show that both the N- and C-terminal domains of MV-V (PNT and VCT) contribute to the inhibition of IFN-α/β signaling. Using the two-
hybrid system and co-affinity purification experiments, we identified STAT1 and Jak1 as interactors of MV-V and demonstrate that MV-V can
block the direct phosphorylation of STAT1 by Jak1. A deleterious mutation within the PNT domain of MV-V (Y110H) impaired its ability to
interact and block STAT1 phosphorylation. Thus, MV-V interacts with at least two components of IFN-α/β receptor complex to block
downstream signaling.
© 2007 Elsevier Inc. All rights reserved.Keywords: Measles; Virus; V; IFN-α/β; Jak1; STAT1Introduction
Interferons α and β (IFN-α/β) are essential mediators of the
innate immune response against viruses (Stetson andMedzhitov,
2006; van Boxel-Dezaire et al., 2006). IFN-α/β signal through
direct binding to a cell surface receptor composed of two trans-
membrane subunits, IFNAR1 and IFNAR2c (Darnell et al.,
1994). To transduce signals, this receptor relies on two members
of the Janus tyrosine kinase (JAK) family, Tyk2 and Jak1, which
constitutively bind IFNAR1 (interferon-α receptor 1 subunit)
and IFNAR2c, respectively (Muller et al., 1993; Velazquez et al.,
1992). Jak1 and Tyk2 sequences exhibit seven regions, JH1 to⁎ Corresponding author. Fax: +33 1 40 61 31 67.
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doi:10.1016/j.virol.2007.06.037JH7, that are conserved among members of the Jak family.
Although their functions are not yet fully understood, JH1 is
known to encode the kinase domain, JH2 represents a pseu-
dokinase domain, and the amino-terminal domains JH3 to JH7
have been implicated in receptor association (Kisseleva et al.,
2002). Two members of the signal transducer and activator of
transcription (STAT) family, STAT1 and STAT2, are also
essential components of this pathway (Stark et al., 1998). Six
conserved domains have been identified through structural and
functional analysis of STAT proteins, including a DNA-binding
region, a SRC homology 2 (SH2) domain that ensures inter-
action with phosphorylated tyrosines, and a transcriptional acti-
vation domain (Kisseleva et al., 2002). Upon binding of IFN-
α/β to its receptor, activated Jak1 and Tyk2 phosphorylate
IFNAR1/2c cytoplasmic tails on tyrosine residues. These phos-
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IFNAR1, its phosphorylation by Jak kinases, and the recruitment
of STAT1 to phosphorylated STAT2 (Li et al., 1997). Phos-
phorylation of STAT1 finally triggers STAT1-STAT2 hetero-
dimerization via SH2-phosphotyrosine interactions, and the
release of this complex from the receptor. Together with the
STAT-associated factor IRF9, STAT1 and STAT2 assemble into
a heterotrimeric complex known as the IFN-stimulated gene
factor 3, ISGF3 (Levy et al., 1989). ISGF3 accumulates in the
nucleus where it binds conserved IFN-stimulated response
element (ISRE) sequences, and stimulates the expression of an
antiviral gene cluster.
Paramyxoviruses have evolved the ability to block the in-
duction of these genes through interference with IFN-α/β sig-
naling pathway (Horvath, 2004). Avirus-encoded protein called
V is a major player of interferon evasion by Paramyxoviruses
from Rubulavirus, Henipavirus, Respirovirus and Morbilli-
virus genera (Fields et al., 2001). All these viruses share
common structural and genetic elements. Their genome is a
single-strand RNAmolecule that encodes six structural proteins.
While hemagglutinin (H) and fusion (F) are transmembrane
glycoproteins of the envelop, the nucleoprotein (N), the phos-
phoprotein (P), the viral polymerase (L) and the matrix protein
(M) are internal to viral particles. The P locus also encodes
nonstructural virulence factors, in particular V and C proteins
(Bellini et al., 1985; Cattaneo et al., 1989). The C protein is
encoded by an opened reading frame embedded in the first half
of the P cistron. Moreover, an unusual editing strategy allows the
insertion of non-templated guanine nucleotide at a specific
position of P-encoded mRNAs (Fig. 1A). Thus, approximately
half of P-encoded mRNAs are edited and encode for V, a protein
similar to P in its amino-terminal part (PNT domain), but with a
unique cysteine-rich C-terminus (VCT) (Cattaneo et al., 1989).Fig. 1. (A) Diagrams of MV-P and MV-V. The position of the RNA editing site, and m
indicated. (B) Inhibition of IFN-β signaling by MV-V proteins depends both on the
pRL-CMV, and pEGFP-C1 expression plasmids encoding indicated proteins. 24 h
incubation, the relative luciferase activities of IFN-treated cells were determined
(C) Expression levels of MV-V protein in transfected or infected HEK-293T cells. Ce
infected with 1 MOI of Schwarz virus then incubated for 24 h and 48 h, respectivelParamyxoviridae V proteins interfere with IFN-α/β signaling
through interaction with STATs, but each genus within the
family exhibits specific mechanisms of inhibition. Rubula-
viruses, including mumps virus, SV5 and human parainfluenza
virus type 2 (HPIV2), are able to recruit the cellular DDB1-
Cul4A-Roc1 E3 complex to promote the rapid ubiquitination
and degradation of the STAT proteins (Didcock et al., 1999;
Parisien et al., 2001, 2002; Ulane et al., 2005; Yokosawa et al.,
2002). Henipavirus V proteins sequester STAT1 and STAT2 in
high-molecular-mass cytoplasmic complexes without inducing
their degradation (Rodriguez and Horvath, 2004). Similarly, the
V protein of measles virus (MV-V), the prototype of Morbilli-
virus genus, does not degrade STAT1 and 2, but effectively
prevents their nuclear import (Palosaari et al., 2003). Whether
MV-Vonly sequesters STAT1/2 in the cytoplasm, or also inhibits
their phosphorylation after IFN-α/β stimulation remains con-
troversial (Palosaari et al., 2003; Takeuchi et al., 2003; Yokota et
al., 2003). Immunoprecipitation experiments performed onMV-
infected cell using antibodies against IFNAR1 and RACK1, a
scaffold protein interacting with IFNAR2c and latent STAT1,
indicated that IFN-α/β receptor forms a tight complex contain-
ing the C and V proteins (Yokota et al., 2003). Other affinity
purification experiments demonstrated that tagged MV-V asso-
ciates with several cellular partners in a protein complex that
includes at least STAT1, STAT2, STAT3, and IRF9 (Palosaari
et al., 2003).
The Edmonston infectious clone (Ed-tag; Radecke et al.,
1995) encodes an attenuated measles virus that fails to induce a
protective immune response in monkeys (Combredet et al.,
2003). The MV-V protein encoded by Ed-Tag virus does block
IFN-α/β signaling, and two deleterious mutations, Y110H and
C272R (Fig. 1A), were mapped within the PNT and the VCT
domains, respectively (Ohno et al., 2004; Radecke et al., 1995).utations Y110H and C272R that are characteristic of Ed-Tag infectious clone are
PNT and the VCT domains. HEK-293T cells were transfected with pISRE-Luc,
after transfection, 1000 IU/ml of recombinant IFN-β was added. After 24 h of
. Experiments were performed in triplicates, and data represent means±SD.
lls were transfected with 1 μg/well of pEGFP-C1 plasmid encoding MV-VSch or
y. After cells lysis, MV-V expression level was analyzed by Western blot.
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suggesting that the two domains of MV-V can independently
affect IFN-α/β signaling. So far, it has not been demonstrated
that an isolated VCT domain inhibits IFN-α/β signaling, but the
PNT domain was clearly shown to do so unless the Y110H
mutation is introduced (Ohno et al., 2004). Interestingly, it was
shown that MV-P, that shares the PNT domain with MV-V, can
also prevent STAT phosphorylation and translocation to the
nucleus, thanks to its amino-terminal domain (Devaux et al.,
2006). In the present study, we investigated the molecular
mechanisms of IFN-α/β signaling inhibition by MV-V protein
and its domains. Identification of direct cellular targets by
combined yeast two-hybrid and co-affinity purification was
achieved, leading to the identification of STAT1 and Jak1 as
interactors of MV-V. We further demonstrated that MV-V, or the
PNT domain alone, can block the direct phosphorylation of
STAT1 by Jak1. Interestingly, Y110H mutation was shown to
impair MV-V inhibitory function, and specifically prevent inter-
action with STAT1, accounting for the loss-of-function pheno-
type of this mutant.
Results
Both the PNT and VCT domains of MV-V contribute to the
inhibition IFN-α/β signaling
MV-V from Edmonston-ATCC or IC-B strains, but not Ed-
tag, inhibits the transactivation of ISRE-luciferase reporter genes
by IFN-α (Devaux et al., 2006; Ohno et al., 2004). Using a
similar reporter assay, we show that MV-V from Schwarz
vaccine and wild-type strains IC-B and G954 behaves accord-
ingly, and strongly inhibits the transactivation of the ISRE-
luciferase reporter gene by IFN-β (Fig. 1B). MV-V protein was
expressed by transient transfection of a CMV-driven plasmid
and its expression level was similar to that observed during MV
infection. Therefore, it can be considered as physiological (Fig.
1C). A combination of twomutations specific ofMV-V fromEd-
tag was shown to impair its function: Y110H in the PNT domain
and C272R in the VCT region (Ohno et al., 2004). Both muta-
tions are required to abrogate MV-Vactivity, suggesting that the
two domains independently contribute to the inhibition of IFN-Fig. 2. MV-V interaction with STAT1 and Jak1 is mediated by the PNT domain of
MDA5 or PIRH2 was analyzed in the yeast two-hybrid system. Yeast cells expressing
transformed by gap-repair (see Materials and methods) with a plasmid encoding the
panel). Because MV-V is a strong self-transactivator, interaction-dependent express
100 mM 3-AT. Same experiments were performed with the PNT and the VCT doma
transactivators, yeast cells were plated on a growth medium supplemented with onlyα/β signaling. Thus, we tested separately the PNT and VCT
domains of MV-V proteins in our reporter assay (Fig. 1B).
Inhibition of IFN-α/β pathway was observed with the PNT
domain alone as previously reported (Ohno et al., 2004), but was
only partial when compared with full-length MV-V protein.
Surprisingly, the VCT domains of Schwarz, IC-B and G954
strains also inhibited IFN-α/β signal transduction. This
observation should be related to the reported interaction of the
VCT domain of mumps virus V protein with RACK1, a key
adaptor that recruits STAT1 to IFN-α/β receptor (Kubota et al.,
2002). These results suggest that both the PNT and VCT
domains of MV-V participate to the inhibition IFN-α/β sig-
naling through interactions with cellular targets.
Yeast two-hybrid screens identified Jak1 and STAT1 as MV-V
interacting proteins
To identify cellular partner(s) of MV-V protein, a human
spleen cDNA library was screened by yeast two-hybrid using
full-length MV-V proteins and corresponding PNT and VCT
domains as baits. Proteins from the two wild-type (IC-B and
G954), and one vaccine (Schwarz) strains were screened in
parallel experiments. Full-length MV-V proteins from G954 and
Schwarz and the PNT domain from IC-B identified STAT1 as an
interactor in this system (11, 2 and 12 hits, respectively). In all
cases, only cDNAs corresponding to full-length STAT1 were
isolated. In addition, Jak1 kinase was isolated when screening
with MV-V proteins from Schwarz and IC-B, and the PNT
domain from IC-B (1, 1 and 3 hits, respectively). In all cases,
cDNAs recovered corresponded to the tyrosine kinase domain of
Jak1 (Jak1-TK, AAs 894-1154). To confirm these interactions,
MV-V from all three strains and corresponding domains were
retested in a pairwise setting against STAT1 or Jak1-TK (Fig. 2
and data not shown). MDA5, a known interactor of the VCT
domain (Childs et al., 2007) that we also identified in our
screens, was used as a positive control. A specific interactor of
the phosphoprotein C-terminus, PIRH2, was used as a negative
control (Chen et al., 2005). As shown in Fig. 2, MV-V and the
PNT domain but not the VCT domain retested against STAT1
and Jak1-TK. In agreement with literature, MDA5 was found to
bind MV-Vor the VCT domain but not the PNT domain, whileMV-V. Interaction of MV-V or its domains (PNT and VCT) with STAT1, Jak1,
MV-V from IC-B strain fused to the Gal4 DNA-binding domain (BD) were co-
Gal4 transactivation domain (AD) fused to indicated cellular prey proteins (left
ion of HIS3 reporter gene was tested on a growth medium supplemented with
ins of MV-V from IC-B strain. Because these two domains are not autonomous
10 mM 3-AT to test interactions.
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teins of all three strains interacted similarly with STAT1 and
Jak1-TK regardless of the viral strain tested (data not shown).
The fact that STAT1 and Jak1-TK were not originally isolated
with all MV-V proteins and PNT domains is inherent to the high
false-negative rate of the two-hybrid system (Ito et al., 2001).
These data suggest that MV-V interacts directly with STAT1 and
Jak1, two major components of IFN-α/β signaling pathway, and
that AAs 1–231 of MV-V that define the PNT domain are
sufficient to mediate these interactions. Identification of the
cellular proteins targeted by the VCT domain of MV-V to block
IFN-α/β signaling will require additional investigations.Fig. 3. MV-V proteins from wild-type and vaccinal MV strains interact with Jak1
encoding GSTalone or fused to MV-V proteins from G954 (MV-VG954), IC-B (MV-V
from transfected cells were prepared 48 h post-transfection (cell lysate; middle and l
sepharose beads (GST pull-down; upper panel). 3xFLAG- and GST-tagged proteins
were co-transfected with GST alone or GST-Jak1, and 3xFLAG-tagged MV-V protein
and 3xFLAG-tagged STAT1 (left panel), or GSTalone, GST-STAT1 and 3xFLAG-tag
transfected with GST alone or fused to indicated MV-V proteins, and 3xFLAG-taggMV-V interacts with STAT1 and Jak1 in mammalian cells
To verify interactions identified by yeast two-hybrid in
mammalian cells, we performed co-affinity purification experi-
ments. First, HEK-293Tcells were transfected with MV-V fused
to glutathione-S-transferase (GST-MV-V) and 3xFLAG-tagged
STAT1 (Fig. 3A). Interaction of MV-V with STAT1 was
confirmed in this system (Fig. 3A), and binding efficiency to
STAT1 was equivalent for all three strains, regardless of their
wild-type (IC-B and G954) or vaccine (Schwarz) status. Similar
experiments were performed to demonstrate that MV-V interacts
with Jak1. However, non-specific binding of Jak1 to sepharoseand STAT1. (A) HEK-293T cells were co-transfected with expression vectors
IC-B) or Schwarz strain (MV-VSch), and either 3xFLAG-STAT1. Total cell lysates
ower panels), protein complexes were assayed by pull-down using glutathione-
were detected by immunoblotting. (B) Similar experiment, but HEK-293T cells
s. (C) Same experiment but cells were co-transfected with GST alone, GST-Jak1
ged Jak1-TK (right panel). (D) Similar experiment, but HEK-293Tcells were co-
ed Jak1-TK.
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two protein tags, and perform experiments with the GST and
3xFLAG tags fused to Jak1 and MV-V, respectively. Co-affinity
purification demonstrated the specific interaction of full-length
Jak1 with MV-V proteins of all three strains (Fig. 3B).
We identified Jak1 as a direct interactor of MV-V in the yeast
two-hybrid system. Because STAT1 was previously reported to
interact with Jak1 by its SH2 domain (Gupta et al., 1996), there is
a possibility that Jak1 interaction with endogenous STAT1
contributes to MV-V co-purification with GST-Jak1. Interest-
ingly, the kinase domain of Jak1 identified by yeast two-hybrid,
and reported here as Jak1-TK, does not interact with STAT1
when co-expressed in HEK-293T cells (Fig. 3C). This suggests
that Jak1-binding region to STAT1 is not localized within Jak1-
TK domain, in agreement with previous reports that localized the
STAT-binding site in the pseudokinase region (JH2) of Jak
kinases (Fujitani et al., 1997). We thus tested if MV-V could co-
purify with Jak1-TK independently of any interaction withFig. 4. Binding of the PNT domain of MV-V to STAT1 and Jak1, and consequences o
encoding GST fused to the PNT or VCT domains of MV-VG954, and either 3xFLAG-
were assayed by pull-down using glutathione-sepharose beads. 3xFLAG- and GST-ta
block IFN-α/β signaling. HEK-293T cells were transfected with pISRE-Luc, pRL-C
24 h after transfection, 1000 IU/ml of recombinant IFN-β were added. After 24 h of i
Experiments were performed in triplicates, and data represent means±SD. (D and E) C
MV-VSch or MV-VSch-Y110H, and either 3xFLAG-STAT1 (D) or 3xFLAG-Jak1-TK (E
proteins were detected by immunoblotting.STAT1. HEK-293T cells were transfected with GST-MV-V and
3xFLAG-tagged Jak1-TK (Fig. 3D). The interaction of MV-V
with Jak1-TK was confirmed in this system, and the binding
efficiency was the same for all three strains tested. These results
confirmed our two-hybrid data, and verified MV-V direct
interaction with both STAT1 and Jak1.
MV interaction with STAT1, but not Jak1, depends on tyrosine
110 in the PNT domain
The PNT domain of MV-V alone interacts with STAT1 or
Jak1 in the yeast two-hybrid system. To validate this observation
by co-affinity purification, HEK-293T cells were co-transfected
with GST-tagged PNT or VCT domains of MV-VG954, and
3xFLAG-tagged STAT1 or Jak1-TK. STAT1 was shown to
interact with the PNT domain, but not the VCT domain of MV-
VG954 (Fig. 4A). On the contrary, we could not co-purify Jak1-
TK with the PNT domain alone (Fig. 4B). This interaction isf Y110H mutation. (A and B) Cells were co-transfected with expression vectors
STAT1 (A) or 3xFLAG-Jak1-TK (B). 48 h post-transfection, protein complexes
gged proteins were detected by immunoblotting. (C) MV-VSch-Y110H capacity to
MV, and pEGFP-C1 expression plasmids encoding MV-VSch or MV-VSch-Y110H.
ncubation, the relative luciferase activities of IFN-treated cells were determined.
ells were co-transfected with expression vectors encoding GSTalone or fused to
). After pull-down using glutathione-sepharose beads, 3xFLAG- and GST-tagged
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fication, while it could be detected in the yeast two-hybrid
system which is known to be more sensitive. When expressed
without the VCT region, the PNT domain is probably unable to
properly fold as suggested by structural data (Li et al., 2006).
Thus, one possibility to explain the discrepancy between yeast
two-hybrid and co-affinity purification data is that the PNT
domain cannot form a stable complex with Jak1-TK in
mammalian cells unless it is structurally constrained through
interactions with the VCT region of MV-V (see discussion).
Previous reports demonstrated that Y110H mutation, either
introduced alone in MV-P or when combined to C272R in
MV-V, impairs the PNT domain ability to block IFN-α/β
signaling (Devaux et al., 2006; Ohno et al., 2004). In our reporter
assay, we found that Y110H single mutation partially impaired
the inhibition of IFN-α/β signaling byMV-V (Fig. 4C). We then
tested the effect of this mutation on MV-V capacity to bind to
STAT1 or Jak1-TK. Co-affinity purification experiments were
performed using either MV-VSch or MV-VSch-Y110H as a bait. As
shown in Fig. 4D, MV-VSch-Y110H interaction with STAT1 was
greatly reduced. In contrast, MV-VSch-Y110H and MV-VSch
interacted with Jak1-TK similarly (Fig. 4E). These observations
suggest that MV-VSch-Y110H is impaired for its ability to block
type I IFN signaling because it cannot bind STAT1, providing
molecular basis for the loss-of-function phenotype of this
mutant.
STAT1 and Jak1 do not compete for binding to the PNT domain
of MV-V
Although Jak1 binding to MV-V relies on the PNT domain
but is independent on tyrosine 110, it remained unclear whether
STAT1 and Jak1 bind simultaneously to MV-V, or compete for
the same region within the PNT domain. Thus, a competitionFig. 5. STAT1 and Jak1 do not compete for binding to the PNT domain of MV-V. Ce
plasmid per well of a 6-well plate), 3xFLAG-Jak1-TK (600 ng/well) and two doses
complexes were assayed by pull-down using streptavidin–metacrylate polymer beads.experiment was designed where MV-VSch or MV-VSch-Y110H
was co-expressed with Jak1-TK in the presence of two different
quantities of STAT1 (Fig. 5). In such setting, STAT1 expression
did not affect Jak1-TK interaction with MV-V, thereby
demonstrating that STAT1 and Jak1 do not compete for the
same binding site within the PNT domain of MV-V. Moreover,
MV-VSch and MV-VSch-Y110H interacted similarly with Jak1-TK
when co-expressed with STAT1 (Fig. 5). This observation also
demonstrates that MV-V binding to Jak1 is not affected by its
interaction with STAT1. These results validate a model where
Jak1 and STAT1 bind to distinct regions in the PNT domain of
MV-V protein.
MV-V binding to STAT1 prevents its direct phosphorylation by
Jak1
Upon IFN-α/β stimulation, Jak1 phosphorylates STAT1
whereas MV-V was reported to block STAT1 phosphorylation
(Takeuchi et al., 2003; Yokota et al., 2003). Our studies showed
thatMV-V interacts both with STAT1 and Jak1, and we therefore
tested its ability to block the direct phosphorylation of STAT1 by
Jak1. Co-expression of Jak1 and STAT1 in mammalian cells can
trigger STAT1 phosphorylation and activation, bypassing the
need for IFN-α/β stimulation (Quelle et al., 1995). Thus, GST-
STAT1 and 3xFLAG-Jak1 were co-expressed in HEK-293T
cells, in the presence or absence of 3xFLAG-tagged MV-V
proteins. After 48 h, the protein extracts were tested for STAT1
phosphorylation status (Fig. 6A). When MV-V proteins from
G954, IC-B or Schwarz were co-expressed, STAT1 phosphor-
ylation was strongly inhibited. This demonstrates thatMV-V can
interfere with the direct phosphorylation of STAT1 by Jak1.
Interestingly, MV-VSch-Y110H was affected in its capacity to
block STAT1 phosphorylation, probably because of the loss of
interaction with STAT1, but still exhibited some inhibitorylls were transfected with BioEase-tagged MV-VSch or MV-VSch-Y110H (200 ng of
of 3xFLAG-STAT1 (either 300 or 60 ng/well). 48 h post-transfection, protein
3xFLAG-tagged and BioEase-tagged proteins were detected by immunoblotting.
Fig. 6. MV-V inhibits STAT1 phosphorylation induced by Jak1 overexpression. (A) HEK-293T cells were co-transfected with expression vectors encoding GST-
STAT1 (600 ng/well), 3xFLAG-Jak1 (10 ng/well), and 3xFLAG-tagged MV-V proteins (300 ng/well) or equal amounts of empty vector. Total cell lysates from
transfected cells were prepared 48 h post-transfection. Phosphorylated STAT1, and 3xFLAG- or GST-tagged proteins were detected by immunoblotting. (B) The same
experiment was performed with the 3xFLAG-PNT domain of MV-VSch (300 ng/well). (C) Cells were co-transfected with expression vectors encoding either Tyk2
kinase-defective mutant K930R (600 ng/well), 3xFLAG-Jak1 (10 ng/well), and 3xFLAG-tagged MV-V proteins (300 ng/well) or equal amounts of empty vector. Total
cell lysates from transfected cells were prepared 48 h post-transfection. Phosphorylated Tyk2, total Tyk2, and 3xFLAG-tagged proteins were detected by
immunoblotting. (D) Cells were co-transfected with 3xFLAG-Jak1 (600 ng/well) and 3xFLAG-tagged MV-V proteins (300 ng/well). Total cell lysates from
transfected cells were prepared 48 h post-transfection. Endogenous phosphorylated STAT1, and 3xFLAG or GST-tagged proteins were detected by immunoblotting.
357G. Caignard et al. / Virology 368 (2007) 351–362activity (Fig. 6A). In such aminimal systemwhere only Jak1 and
STAT1 are overexpressed, this observation suggests that MV-V
interaction with Jak1, that is independent of Y110H mutation, is
responsible for this partial inhibition. To substantiate this hypo-
thesis, additional experiments were performed using Tyk2 in-
stead of STAT1 as a target for Jak1. A kinase-defective mutant of
Tyk2 (K930R) was used to discriminate Tyk2 self-phosphoryla-
tion from its phosphorylation by Jak1. As shown in Fig. 6C,
MV-VSch and MV-VSch-Y110H equally inhibited Tyk2 phosphor-
ylation by Jak1. This observation supports a model whereMV-V
impairs the proper phosphorylation of various Jak1 targets.
It should be noted that transfections were performed with
very low amounts of Jak1 encoding plasmid (10 ng/well of a 6-
well plate). When high amounts of both Jak1 and STAT1
plasmids were used (600 ng/well), inhibition of STAT1
phosphorylation by MV-V was barely detectable, suggesting acompetition between the three elements of the system. To test
this hypothesis, cells were transfected with high amounts of Jak1
(600 ng/ml), and endogenous STAT1 phosphorylation was
detected. In such setting, STAT1 instead of Jak1 is the limiting
factor because endogenous STAT1 is expressed at very low
levels. In the presence of MV-V, endogenous STAT1 phosphor-
ylation was blocked (Fig. 6D). Moreover, MV-VSch-Y110H was
impaired in its ability to prevent STAT1 phosphorylation but this
loss-of-function phenotype was only partial as reported above.
These results demonstrate that MV-V can block endogenous
STAT1 phosphorylation by Jak1, and that Y110H mutation
impairs this function.
Finally, we tested the capacity of the PNT domain alone to
inhibit overexpressed or endogenous STAT1 phosphorylation
(Figs. 6B and D, respectively). Interestingly, this domain is
sufficient to completely block STAT1 phosphorylation, although
358 G. Caignard et al. / Virology 368 (2007) 351–362interaction with Jak1 was unstable and could not be detected by
co-affinity purification (Fig. 4B). This suggests that MV-V
interaction with STAT1 alone is sufficient to block its phos-
phorylation and IFN-α/β signaling. However, reporter gene and
kinase assays performed with the MV-VSch-Y110H mutant (Fig.
4C, Figs. 6A, C and D) suggest that MV-V interaction with Jak1
by the PNT domain and yet unidentified IFN-α/β signaling
components by the VCT region, can partially compensate for the
loss of interaction with STAT1.
Discussion
MV-V is a potent inhibitor of IFN-α/β transduction pathway
that contributes to the hijacking of cellular functions by MV.
This viral protein was shown to associate with IFN-α/β receptor
components in a tight complex that freeze signaling (Palosaari et
al., 2003; Takeuchi et al., 2003; Yokota et al., 2003). We now
demonstrate that both the N- and C-terminal domains of MV-V
(PNT and VCT) contribute to the inhibition of IFN-α/β
signaling. In addition, we identified by yeast two-hybrid and
validated by co-affinity purification experiments the direct
interaction of MV-V both with STAT1 and Jak1. Binding
interfaces map to MV-Vamino-terminal domain (PNT), and the
deleterious mutation Y110H is shown to specifically disrupt
MV-V interaction with STAT1. Finally, we report that MV-V
inhibits the direct phosphorylation of STAT1 by Jak1, providing
some molecular basis to the inhibition of IFN-α/β signaling by
this virulence factor.
MV-V protein is composed of an intrinsically disordered
amino-coterminal region shared with MV-P (PNT), and a highly
conserved zinc-binding carboxyl-terminus domain (VCT).
These two domains are involved in several processes through
interactions with multiple viral and cellular partners. The VCT
domain mediates MV-V oligomerization and interaction with
MDA-5, thereby inhibiting the induction of IFN-α/β by double-
stranded RNA (Childs et al., 2007; Ulane et al., 2005). In
addition, this domain can bind RNA molecules, and such
interactions repress MV genome replication (Parks et al., 2006).
Functional assays also suggest that the VCT domain mediates
MV-V interaction with p53 family member p73 (Cruz et al.,
2006).We now report that the VCT domain alone can block IFN-
α/β signaling. This would explain why a mutation that affects
the PNT domain must be combined with a second mutation in
the VCT region to abrogate MV-V inhibitory capacity (Ohno et
al., 2004). Interestingly, the VCT domain of mumps virus was
reported to interact directly with RACK1 (Kubota et al., 2002),
an adaptor that bridges STAT1 to IFNAR2c, suggesting a
mechanism for the inhibition of IFN-α/β signaling by the VCT
domain of MV.
In contrast to the VCT domain which is self-constrained,
folding of intrinsically disordered polypeptides like the PNT
domain depends on interactions with specific binding partners
(Bourhis et al., 2006). Interaction-induced folding of intrinsi-
cally disordered domains allow them to adopt various structures
with specific binding interfaces. As a consequence, such regions
favor interactions with multiple protein partners, and this is
probably the case for the PNT domain of MV-V (Haynes et al.,2006). The structure of the V protein from simian virus 5 (SV5)
suggests that the PNT domain of MV-V interacts with the VCT
region to adopt a specific folding (Li et al., 2006). But this PNT
domain must be differently folded when it interacts with
components of the replication complex as part of the phospho-
protein P (Bourhis et al., 2006). Inhibition of IFN-α/β signaling
by MV-Vor MV-P relies on this domain, which is sufficient to
block signal transduction downstream of IFNAR1/2c (Ohno
et al., 2004). However, inhibition of IFN-α/β pathway by the
PNT domain alone is only partial when compared with full-
length MV-V protein (Fig. 1B). This supports a critical role for
the VCT region that inhibits IFN-α/β pathway by itself, but
could also contribute to the appropriate folding of the PNT
domain.
We report here that STAT1 and Jak1 are direct interactors of
the PNT domain when expressed in the context of MV-V
protein. STAT1 was previously immunoprecipitated with
FLAG-tagged MV-V as part of a protein complex containing
STAT1, STAT2, STAT3, and IRF9 (Palosaari et al., 2003). Our
yeast two-hybrid data supported by co-affinity experiments
demonstrate that MV-V binds directly to STAT1. This observa-
tion should be related to the reported direct interaction of STAT1
with the V proteins of theMorbillivirus Rinderpest virus (RPV)
and the Henipaviruses (Nanda and Baron, 2006; Rodriguez and
Horvath, 2004). As reported here for MV, the amino-terminal
domains of the V proteins from RPV, Nipah and Hendra viruses
mediate the interaction with STAT1. Interaction with Jak1 is
unexpected, and demonstrates that MV-V impairs IFN-α/β
transduction by interacting with multiple components of this
pathway. The PNT domainmediatesMV-Vinteraction with Jak1
as shown by yeast two-hybrid, but the presence of VCT domain
seems critically required to stabilize this interaction in
mammalian cells. This led us to hypothesize that Jak1 binding
to the PNT domain depends on its appropriate chaperoning by
the VCT region, although this still requires a clear demonstration
based on structural analysis of the complex. Our data also
demonstrate that Jak1 and STAT1 have distinct non-overlapping
binding sites. Thus, MV-V could bind simultaneously to Jak1
and STAT1 if these two cellular proteins are localized in the same
vicinity.
We determined that MV-V binds to the kinase domain (JH1)
of Jak1, a region critically involved in the phosphorylation of
STAT proteins by Jak kinases. In an attempt to map the region of
STAT1 that binds MV-V, STAT1 domains were cloned
individually or in combinations, then tested for interactions
with MV-V (data not shown). None of the constructs interacted
with MV-V, suggesting that only full-length STAT1 is properly
folded and displays the required binding site for MV-V.
Complementary STAT1–STAT3 fusion proteins were pre-
viously used to demonstrate that the C-terminal region of
STAT1 (AA 509–750) mediates the interaction with the V
protein of Nipah virus (Rodriguez et al., 2004). Our data suggest
that a similar strategy should be applied to MV-V. Interestingly,
STAT1 is known to bind Jak1 by interaction of its SH2 domain
with the JH2 pseudokinase domain of Jak1 (Fujitani et al., 1997;
Gupta et al., 1996). This interaction is required for Jak1 to
phosphorylate STAT1 in vitro, and likely represents an essential
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results suggest that MV-V can form a stable heterotrimeric
complex with Jak1 and STAT1, thereby freezing IFN-α/β
receptor. It is tempting to speculate that MV-V has evolved to
interact with STAT1-Jak1 heterodimeric complex at a binding
interface localized at the junction between the two cellular pro-
teins. With this model in mind, we tested whether MV-V can
block the direct phosphorylation of STAT1 by Jak1 kinase. Our
results demonstrate that MV-V inhibits Jak1-mediated phos-
phorylation of overexpressed or endogenous STAT1. This ob-
servation can provide amolecular basis for the inhibition of IFN-
α/β signaling by this viral protein. MV-V was reported to
sequester STAT1 in the cytosol (Palosaari et al., 2003), but our
data sustain reports demonstrating that MV-V can also inhibit
STAT1 phosphorylation in IFN-α/β stimulated cells (Takeuchi
et al., 2003; Yokota et al., 2003).
MV-V from wild-type and vaccine strains have similar
binding capacities for STAT1 and Jak1, and equally inhibit IFN-
α/β signaling. This is expected, as MV vaccine strain must
efficiently replicate in an interferon-competent environment
when injected in vivo to trigger an adaptive immune response.
In contrast, the infectious cDNA clone Ed-Tag encodes a virus
defective for the inhibition of IFN-α/β signaling, and critically
impaired for its capacity to trigger adaptive immunity
(Combredet et al., 2003; Radecke et al., 1995). Mutations
responsible for this deficiency were mapped to tyrosine 110 and
cysteine 272 of MV-V (Ohno et al., 2004). Although mutation
of cysteine 272 is clearly deleterious for the VCT domain zinc
finger, we investigated how the Y110H mutation impairs MV-V
function. As shown in the present study, the Y110H mutation
affects MV-V capacity to block Jak1-mediated phosphorylation
of STAT1. Failure to interact with STAT1 probably explains the
phenotype of this mutant. Our observations raised the possi-
bility that the tyrosine 110 of MV-V might be phosphorylated
by Jak1 or other kinases. So far, we have not been able to detect
the phosphorylation of MV-V on tyrosine residues, even if co-
expressed with excess amounts of Jak1 (data not shown). In
addition, interactions with STAT1 and Jak1 are likely
independent on tyrosine phosphorylation events because (i)
proteins are not phosphorylated on tyrosines in yeast where
interactions have been identified by two-hybrid and, (ii) co-
affinity purification experiments were performed in the absence
of tyrosine phosphatase inhibitors. Thus, our observations
suggest that MV-V is not phosphorylated on tyrosine 110.
Our data also demonstrate that the PNT domain alone binds
STAT1 and blocks its phosphorylation by Jak1, although the
interaction with Jak1 is probably weak or absent when this
domain is separated from the VCT region. Thus, interaction with
STAT1 is essential to explain the capacity of MV-Vor MV-P to
block STAT1 phosphorylation downstream of IFN-α/β receptor.
However, the fact that MV-VSch-Y110H mutant is only partially
impaired for its ability to block STAT1 phosphorylation is
surprising (Fig. 6A). This experiment performed in a minimal
system where only Jak1 and STAT1 are overexpressed suggests
that MV-V interaction with Jak1 is responsible for this inhi-
bition. This model is supported by the observation that MV-V
can block the phosphorylation of another well-characterizedtarget of Jak1, the IFNAR1-associated kinase Tyk2. Although
we cannot exclude that the VCT region targets Jak1-mediated
phosphorylation of STAT1 through interactions with yet un-
identified partners, our data suggest that MV-V interaction with
Jak1 can partially compensate for the loss of interaction with
STAT1. To verify this conjecture, we are planning to generate by
reverse two-hybrid MV-V mutants that fail to interact with Jak1
but remain competent for binding to STAT1. Such mutants will
be instrumental to demonstrate the relative contribution of MV-
V interaction with Jak1 to the inhibition of IFN-α/β signaling.
In conclusion, our data support a model where MV-V blocks
IFN-α/β signaling through interactions with multiple compo-
nents of the pathway including STAT1, Jak1 and at least one yet
unidentified cellular partner of the VCT domain that could be
RACK1. Because of redundancy, this system probably ensures
the complete inhibition of the pathway in MV infected cells.
Materials and methods
ORF cloning and plasmid constructs
All constructs were amplified by standard PCR (ExTaq;
Takara) or RT-PCR (Titan One tube; Roche) methods, and
cloned using a recombinational cloning system (Gateway sys-
tem; Invitrogen) into pDONR207 (Invitrogen) or pDONR223
(kindly provided by D. Esposito and JL. Hartley; Rual et al.,
2004). PCR primers used to amplify and clone viral or cellular
ORFs displayed from 20 to 30 specific nucleotides matching
ORF extremities so that their Tm is close to 60 °C. To achieve
recombinational cloning of PCR products, 5′ ends of forward
primers were fused to attB1.1 recombination sequence 5′-
GGGGACAACTTTGTACAAAAAAGTTGGCATG-3′, while
reverse primers were fused to attB2.1 recombination sequence
5′-GGGGACAACTTTGTACAAGAAAGTTGGTTA-3′. Pri-
mer pairs were designed using the ViralOrfeome interface
(http://www.viralorfeome.com; manuscript in preparation)
developed in collaboration with IFR-128 BioSciences (Lyon,
France) and Modul-Bio (Marseille, France). Recombination of
PCR products into pDONR207 or pDONR223 was performed
following manufacturer's recommendation (BP cloning reac-
tion, Invitrogen). All constructs were transformed and amplified
in Escherichia coli DH5α strain. ORFs of full-length MV-V,
PNT domain (AA 1-231) and VCT domain (AA 232-299) were
amplified by PCR from previously described infectious clones
of Schwarz strain (Genbank ID: AF266291; Combredet et al.,
2003) or IC-B strain (Genbank ID: NC001498; Takeda et al.,
2000), or by RT-PCR on total RNAs extracted from B95a cells
infected with MV strain G954 (Genbank ID: EF472597;
Kouomou andWild, 2002). SinceMV-Vencoding ORF contains
a non-templated extra guanine (G) residue, two step PCRs were
carried out. Two PCR fragments overlapping at the editing site
were amplified from IC-B and Schwarz infectious clones using
either forward or reverse frameshift primers (5′-CATTAAAAA-
GGGGCACAGACGCGAGAT-3′ and 5′-ATCTCGCGT-
CTGTGCCCCTTTTTAATG-3′) that incorporate an extra G
residue at the editing site in combination with attB-containing
primers that hybridize at the extremities of MV-V encoding
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PCR was carried out using only the attB-containing primers. To
clone MV-V ORF from G954 strain, RT-PCR on total RNAs
from infected cells was performed with specific primers. PCR
products were cloned and sequenced to identify cDNAs with an
extra non-templated G residue at the editing site. To clone MV-
VSch-Y110H encoding ORF, pDONR223 plasmids with MV-VSch
or MV-VEd-tag (Radecke et al., 1995) were cut in two with XhoI
and HindIII. Then, fragments were swapped and religated to
create MV-VSch-Y110H with nucleotides 1–613 of MV-VEd-tag
fused to nucleotides 614–900 of MV-VSch. Resulting sequence
is therefore identical to MV-VSch, but carries the Y110H
mutation. ORFs encoding STAT1, Jak1 and Jak1-TK (AAs
894-1154) were amplified from cDNA clones kindly provided
by Dr S. Pellegrini (Pasteur Institute, Paris), then cloned in
pDONR207 (Invitrogen), and sequence verified. Subsequently,
viral or cellular ORFs cloned into pDONR vectors were
transferred by recombinatorial reaction into various Gateway-
compatible destination vectors (see below) following manufac-
turer's recommendation (LR cloning reaction, Invitrogen).
Previously described pRc-K930R vector was kindly provided
by S. Pellegrini (Gauzzi et al., 1996).
Cell culture and transient expression of recombinant proteins
Human HEK-293T cells were maintained in Dulbecco's
modified Eagle's medium (DMEM; Gibco-Invitrogen) contain-
ing 10% fetal bovine serum, penicillin, and streptomycin at
37 °C and 5% CO2. To achieve overexpression in mammalian
cells, cloned ORFs were transferred by recombinational cloning
(Gateway system; Invitrogen) from pDONR223 or pDONR207
to the following expression vectors to achieve GST-fusion
(pDEST27; Invitrogen), 3xFLAG-fusion (pCI-neo-3xFLAG;
Mendoza et al., 2006), biotinylation (pcDNA6/BioEase-DEST;
Invitrogen) or EGFP-fusion (pEGFP-C1; Clontech). Unless
specified, 5×105 cells per well were dispensed in 6-well
plates and transfected 24 h later with 500 ng of each plasmid
DNA per well. The total amount of transfected DNA per
well was normalized using corresponding empty vectors
whenever required. Transfection was performed with Lipo-
fectamine 2000 (Invitrogen) according to manufacturer's
recommendation.
Luciferase reporter gene assay
Expression of IFN-inducible genes was determined by
transiently transfecting reporter plasmids pISRE-Luc containing
the ISRE enhancer element upstream of the firefly luciferase
gene (Stratagene). HEK-293Tcells were plated in 24-well plates
(2×105 per well). One day later, they were transfected with
pISRE-Luc reporter plasmid (1 μg/well), pRL-CMV reference
plasmid that harbored a CMV promoter just upstream of the
Renilla luciferase gene (0.01 μg/well; Promega), and specified
ORFs cloned in pEGFP-C1 vector (1 μg/well). After 24 h, IFN-β
(Biosource) was added to the medium at 1000 IU/ml, and the
cells were incubated for 24 h. The cells were lysed, and the
firefly luciferase and Renilla luciferase activities in the lysateweremeasured using the Dual-luciferase Reporter Assay System
(Promega) following manufacturer's recommendation. Reporter
activity was calculated as the ratio of firefly luciferase activity to
reference Renilla luciferase activity.
Yeast two-hybrid procedure
Yeast culture mediums were prepared as previously described
(Walhout and Vidal, 2001). V, PNT and VCT coding sequences
from IC-B, G954 and Schwarz MV strains were cloned into the
Gal4-BD yeast two-hybrid vector pDEST32 (Invitrogen), and
transformed into AH109 yeast cells (Clontech) according to
standard procedures (Gietz et al., 1995). The GAL4-BD-PNT,
-VCT and -V fusion proteins were tested for autonomous trans-
activation of HIS3 reporter gene. The VCT domains of all three
strains and PNT domains from IC-B and G954 MV strains did
not induce autonomous transactivation, and the screens were
performed on synthetic medium lacking histidine (-His medium)
and supplemented with only 10 mM of 3-amino-1,2,4-triazole
(3-AT; Sigma-Aldrich). As previously reported, the PNT domain
from Schwarz strain was a weak transactivator and the selective
medium for the screen had to be supplemented with 30 mM of 3-
AT (Chen et al., 2003). Some of the few mutations that dis-
criminate the PNT domain of Schwarz from G954 and IC-B, in
particular proline substitutions, probably account for this
difference. Full-length MV-V proteins were all strong transacti-
vators in yeast. A synthetic medium supplemented with 100 mM
of 3-AT was required to titrate this activity and prevent yeast
growth in the absence of interactor. As previously described
(Fromont-Racine et al., 1997), a mating strategy was used for
screening the human spleen cDNA library cloned in the GAL4-
AD pPC86 vector (Invitrogen) and previously transformed into
the yeast strain Y187 (Clontech). After 6 days of culture on
selective medium, [His+] colonies were picked, purified during
3 weeks by culturing on selective medium to eliminate false-
positives (Vidalain et al., 2004). AD-cDNAs were amplified by
PCR from zymolase-treated yeast colonies using primers (AD
and Term; Walhout and Vidal, 2001) that hybridize within the
pPC86 regions flanking cDNA inserts. PCR products were
sequenced, and cellular interactors were identified by blast
analysis (Louis M. Jones, Institut Pasteur). These PCR products
were also used to retest interactions between viral baits and
cellular preys following the gap-repair procedure (Walhout and
Vidal, 2001). Briefly, 250 ng of linearized pPC86 empty vector
was co-transformed with 5 μl of PCR product to allow
recombinatorial repair in fresh yeast cells expressing BD-fused
MV-Vor its domains. AD-fused cDNAs encoding STAT1 (AAs
1-750), Jak1 (AAs 894-1154), MDA5 (AAs 577-1025) and
PIRH2 (AAs 63-261) were retested in yeast cells using this
procedure.
Cell lysis and co-affinity purifications
Two days after transfection, HEK-293T cells were washed in
phosphate-buffered saline (PBS), then treated with lysis buffer
(0.5% Nonidet P-40, 20 mM Tris–HCl at pH=8, 120 mM NaCl
and 1 mM EDTA), supplemented with Complete Protease
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(Sigma-Aldrich) when testing STAT1 or Tyk2 phosphorylation.
Cell lysates were incubated on ice for 20 min, then clarified by
centrifugation at 14,000×g for 10 min. For pull-down analysis,
400 μg of protein extracts was incubated for 1 h at 4 °C with
either 25 μl of glutathione-sepharose beads (Amersham
Biosciences) to purify GST-tagged proteins, or 25 μl of
streptavidin–metacrylate polymer beads (Boehringer Man-
nheim) to purify biotinylated BioEase-tagged proteins, respec-
tively. Beads were then washed 3 times in ice-cold lysis buffer
and proteins were recovered by boiling in denaturing loading
buffer (Invitrogen).
Western blot analysis
Purified complexes and protein extracts were resolved by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 4–
12% NuPAGE Bis–Tris gels with MOPS running buffer
(Invitrogen), and transferred to a nitrocellulose membrane with
the iBlot Dry blotting system (Invitrogen). 3xFLAG- and GST-
tagged proteins were detected using standard immunoblotting
techniques. Membranes were blotted with a mouse monoclonal
HRP-conjugated anti-3xFLAG antibody (M2; Sigma-Aldrich)
or a rabbit polyclonal anti-GST antibody (Sigma-Aldrich).
Endogenous STAT1 and STAT1 phosphorylated at position
Y701 were revealed using clone-1 and clone-14, respectively
(mouse monoclonal antibodies; BD Biosciences). MV-VSch was
detected using a rabbit polyclonal antibody kindly provided by
Dr. Kaoru Takeuchi (Takeuchi et al., 2003). Phospho-Tyk2 and
Tyk2 were detected using a rabbit polyclonal antibody
(Calbiochem) and the previously described mouse monoclonal
antibody T10-2 (Gauzzi et al., 1996), respectively. Secondary
anti-mouse and anti-rabbit HRP-conjugated antibodies were
from GE-Healthcare and Amersham, respectively. Biotinylated
BioEase-tagged proteins were detected using HRP-conjugated
streptavidin (Invitrogen).
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